G1 Therapeutics, Inc. 3 SEC Filings

Filed On	Filing
24 May 2023	Form 3: Thomas Monica R., General Counsel Holds 176 shares of Common Stock
17 Mar 2023	Form 3: Umstead John V., Chief Financial Officer Holds 8,886 shares of Common Stock
02 Aug 2022	Form 3: Sharpless Norman, Director No securities owned
29 Jun 2022	Form 3: Lee Jacks, Director No securities owned
17 Aug 2021	Form 3: Perry Andrew, Chief Commercial Officer Holds 20 shares of Common Stock
21 Jun 2021	Form 3: Secor Alicia, Director No securities owned
01 Apr 2020	Form 3: Gupta Soma, Chief Commercial Officer No securities owned
13 Mar 2020	Form 3: Bailey John E. (Jack) Jr., Director No securities owned
30 Jul 2019	Form 3: Avagliano Mark, Chief Business Officer No securities owned
13 Sep 2018	Form 3: Nicholson Garry A, Director No securities owned
06 Jul 2018	Form 3: Demaree John, Chief Commercial Officer Holds 4,250 shares of Common Stock
27 Jun 2018	Form 3: Hanson James S., General Counsel Holds 1,000 shares of Common Stock
11 Jun 2018	Form 3: Schwalm Cynthia, Director Holds 80 shares of Common Stock
11 Jun 2018	Form 3: Deese Willie A, Director No securities owned
15 Nov 2017	Form 3: Phillips Barclay A, SVP & Chief Financial Officer No securities owned
03 Aug 2017	Form 3: Murdock Terry L, SVP of Development Operations No securities owned
13 Jul 2017	Form 3: Witty Andrew, Director No securities owned
19 May 2017	Form 3: Sullivan Timothy Eugene, Director No securities owned
17 May 2017	Form 3: Eshelman Fredric N, Director and 1 other
17 May 2017	Form 3: MedImmune Ventures, Inc., 10% owner

Comments